Grand Pharma (China) Co., Ltd. originated as Wuhan Pharmaceutical Factory, established in 1939 within the revolutionary base of the Taihang Mountains. In 2002, it underwent an asset reorganization with the China Grand Enterprise Inc. Grand Pharma is a publicly traded company in China that is noteworthy for its focus on both innovative pharmaceuticals and high-end medical devices. Through years of growth and accumulation of expertise, the company has established comprehensive coverage in the domains of cardiovascular and cerebrovascular diseases, oncology, and respiratory disorders.

Tags

Other Diseases

Neoplasms

Infectious Diseases

Small molecule drug

Therapeutic radiopharmaceuticals

Diagnostic radiopharmaceuticals

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	15
Infectious Diseases	14
Nervous System Diseases	12
Immune System Diseases	7
Endocrinology and Metabolic Disease	5
Hemic and Lymphatic Diseases	4

Top 5 Drug Type	Count

Small molecule drug	24
Therapeutic radiopharmaceuticals	5
Chemical drugs	3
Radionuclide Drug Conjugates (RDC)	3
Diagnostic radiopharmaceuticals	3

Top 5 Target	Count

CAIX(Carbonic anhydrase IX)	2
PSMA(Prostate-specific membrane antigen)	2
histone	1
GR(Glucocorticoid receptor)	1
IL-12(Interleukin-12)	1

Drugs associated with Grand Pharmaceutical (China) Co., Ltd.

Gallium GA-68 Gozetotide

Target

PSMA

Mechanism

PSMA inhibitors [+1]

Active Org.

Telix Pharmaceuticals (US), Inc. [+11]

Originator Org.

The University of California, San Francisco

Active Indication

Metastatic castration-resistant prostate cancer [+11]

Inactive Indication

Adenocarcinoma of prostate [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Dec 2020

An'ningpai changrongruan jiaonang

Target-

Mechanism-

Active Org.

Beijing Jiu He Pharmaceutical Ltd.

Originator Org.

Beijing Jiu He Pharmaceutical Ltd.

Active Indication

Sinusitis [+4]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date28 Aug 2020

Olopatadine Hydrochloride/Mometasone Furoate Monohydrate

Target

GR x H1 receptor

Mechanism

GR agonists [+1]

Active Org.

Glenmark Specialty SA [+4]

Originator Org.

Glenmark Pharmaceuticals Ltd.

Active Indication

Rhinitis, Allergic, Seasonal [+1]

Inactive Indication

Rhinitis perennial [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date11 Dec 2019

Clinical Trials associated with Grand Pharmaceutical (China) Co., Ltd.

CTR20242487 / Active, not recruitingNot Applicable

福多司坦片人体生物等效性试验

[Translation] Bioequivalence study of fudosteine tablets in humans

采用单中心、随机、开放、两制剂、两周期交叉、单剂量给药设计，分别在空腹和餐后给药条件下，比较湖北舒邦药业有限公司提供的福多司坦片（规格： 0.2 g）与田辺三菱製薬株式会社持证的福多司坦片（规格： 0.2 g，商品名： Cleanal®）在中国健康人群中吸收程度和吸收速度的差异，并评价湖北舒邦药业有限公司提供的福多司坦片的安全性。

[Translation]

A single-center, randomized, open-label, two-preparation, two-cycle crossover, and single-dose dosing design was adopted to compare Fudosteine tablets provided by Hubei Shubon Pharmaceutical Co., Ltd. (Specifications: 0.2 g) and Tabe Mitsubishi Co., Ltd.’s certified fudosteine tablets (specification: 0.2 g, trade name: Cleanal®) in the degree and rate of absorption in Chinese healthy people, and to evaluate the differences in the absorption rate of Hubei Shubon Pharmaceuticals Safety of Fodorsteine Tablets offered by Ltd.

Start Date12 Aug 2024

Sponsor / Collaborator

Hubei Shubang Pharmaceutical Co Ltd.

CTR20241423 / RecruitingPhase 1

一项评估GPN00884滴眼液在健康成人受试者中单次及多次给药后安全性、耐受性和药代动力学特征的随机、双盲、安慰剂平行对照、剂量递增的I期临床研究

[Translation] A randomized, double-blind, placebo-controlled, dose-escalating Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of GPN00884 eye drops after single and multiple doses in healthy adult subjects

主要目的：评价GPN00884滴眼液在健康受试者中单次及多次给药后的安全性和耐受性。次要目的：评价GPN00884滴眼液在健康受试者中单次及多次给药后的药代动力学（PK）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of GPN00884 eye drops after single and multiple administrations in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of GPN00884 eye drops after single and multiple administrations in healthy subjects.

Start Date04 Jun 2024

Sponsor / Collaborator

Hubei Dongsheng Pharmaceutical Co. Ltd.

[+1]

CTR20241675 / CompletedNot Applicable

远大医药（中国）有限公司生产的比拉斯汀片（20 mg）与原研参比制剂（20 mg）在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期、双交叉空腹状态下的人体生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-period, double-crossover bioequivalence study of bilastine tablets (20 mg) produced by Yuanda Pharmaceutical (China) Co., Ltd. and the original reference preparation (20 mg) in healthy Chinese subjects under fasting conditions

以远大医药（中国）有限公司生产的比拉斯汀片（规格：20 mg）为受试制剂，FAES FARMA, S.A生产的比拉斯汀片（商品名：BILAXTEN，规格：20 mg）为参比制剂，考察两制剂在空腹状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性。

[Translation]

Bilastine tablets (specification: 20 mg) produced by Yuanda Pharmaceutical (China) Co., Ltd. were used as the test preparation, and Bilastine tablets (trade name: BILAXTEN, specification: 20 mg) produced by FAES FARMA, S.A. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration under fasting conditions were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety of the two preparations in healthy humans was evaluated.

Start Date21 May 2024

Sponsor / Collaborator

Grand Pharmaceutical (China) Co., Ltd.

100 Clinical Results associated with Grand Pharmaceutical (China) Co., Ltd.

0 Patents (Medical) associated with Grand Pharmaceutical (China) Co., Ltd.

Literatures (Medical) associated with Grand Pharmaceutical (China) Co., Ltd.

01 Dec 2024·Applied Microbiology and Biotechnology

Engineering the Tat-secretion pathway of Bacillus licheniformis for the secretion of cytoplasmic enzyme arginase

Article

Author: Li, Junliang ; Wang, Qin ; Xing, Panpan ; Ji, Yi ; Pi, Li ; Chen, Shouwen ; Liang, Yonglin ; Wang, Yajun ; Li, Liang ; Nomura, Christopher T ; Zhu, Chengjun

The industrial bacterium Bacillus licheniformis has long been used as a microbial factory for the production of enzymes due to its ability to secrete copious amounts of native extracellular proteins and its generally regarded as safe (GRAS) status. However, most attempts to use B. licheniformis to produce heterologous and cytoplasmic enzymes primarily via the general secretory (Sec) pathway have had limited success. The twin-arginine transport (Tat) pathway offers a promising alternative for the extracellular export of Sec-incompatible proteins because it transports full, correctly folded proteins. However, compared to the Sec pathway, the yields of the Tat pathway have historically been too low for commercial use. To improve the export efficiency of the Tat pathway, we identified the optimal Tat-dependent signal peptides and increased the abundance of the Tat translocases, the signal peptidase (SPase), and the intracellular chaperones. These strategic modifications significantly improved the Tat-dependent secretion of the cytoplasmic enzyme arginase into the culture medium using B. licheniformis. The extracellular enzymatic activity of arginase showed a 5.2-fold increase after these modifications. Moreover, compared to the start strain B. licheniformis 0F3, the production of extracellular GFP was improved by 3.8 times using the strategic modified strain B. licheniformis 0F13, and the extracellular enzymatic activity of SOX had a 1.3-fold increase using the strain B. licheniformis 0F14. This Tat-based production chassis has the potential for enhanced production of Sec-incompatible enzymes, therefore expanding the capability of B. licheniformis as an efficient cellular factory for the production of high-value proteins. KEY POINTS: • Systematic genetic modification of Tat-pathway in B. licheniformis. • Significant enhancement of the secretion capacity of Tat pathway for delivery the cytoplasmic enzyme arginase. • A new platform for efficient extracellular production of Sec-incompatible enzymes.

01 Sep 2024·Poultry Science

Dietary Bacillus velezensis KNF-209 supplementation improves growth performance, enhances immunity, and promotes gut health in broilers

Article

Author: Liu, Ying ; He, Wenjun ; Xiong, Mengqin ; Zang, Jianjun ; Yang, Wenjun ; Li, Yongchen ; Hu, Xiao ; Chen, Yiqiang ; Zhang, Wanjun ; Luo, Sunlin

This study aimed to investigate the effects of dietary Bacillus velezensis KNF-209 (BV-KNF-209) on the growth performance, immunity, and gut health of broilers. A total of 540 one-day-old male Cobb-500 broilers were randomly divided into 5 groups of 6 replicates with 18 broilers per replicate. Dietary treatments were corn-soybean meal basal diets supplemented with 0, 50, 100, 200, and 400 mg/kg BV-KNF-209 (CON, BV 50, BV 100, BV 200, and BV 400 groups, respectively) for 42 d. Compared with the CON group, the average daily gains (ADG) at 0 to 42 d in the BV 100 and BV 200 groups were significantly increased (P < 0.01), and the feed-to-gain (F:G) ratios were significantly decreased at 0 to 21 d (P < 0.01) and 0 to 42 d (P < 0.05). The BV 200 and BV 400 groups had higher serum immunoglobulin M (IgM) levels at d 21 and 42 (P < 0.05). The serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) were significantly decreased in the BV 50, BV 100, and BV 200 groups at d 21 (P < 0.05), and serum IL-1β and IL-6 levels were also reduced in the BV 100 and BV 200 groups at d 42 (P < 0.05). Meanwhile, increased interleukin-10 (IL-10) levels in the jejunal and ileal mucosa at d 42 were observed in the BV 100, BV 200, and BV 400 groups (P < 0.05), while the IL-1β and IL-6 levels (P < 0.01) were decreased. The BV 200 and BV 400 groups showed significantly higher activities of lipase and trypsin (P < 0.05) in jejunal digesta as well as higher activities of amylase and trypsin (P < 0.01) in ileal digesta at d 42. The cecal acetic acid and propionic acid levels in the BV groups and lactic acid levels in the BV 50, BV 100, and BV 200 groups (P < 0.05) were significantly higher compared to those in the CON group. Overall, dietary BV-KNF-209 supplementation significantly improved broiler growth performance, an effect that may have been achieved by heightening immunity, increasing digestive enzyme activity, and raising intestinal short-chain fatty acids and lactic acid levels.

03 Apr 2023·Molecular pharmaceutics

Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.

Article

Author: Li, Xiaoxu ; Clark, Andrew R ; Wu, Song ; Qiu, Mingxing ; Liao, Xiaoyan ; Cheng, Xinwei ; Wang, Jiong ; Zheng, Chaoran ; Bai, Jiaojiao ; Zhou, Xiaoju ; Lee, Robert J ; Tian, Cuiqing ; Liu, Zhi

Hepatocellular carcinoma (HCC) is one of the most common cancers, with high mortality. Chemotherapy is one of the main treatment options for HCC. However, the high toxicity and poor specificity of chemotherapeutic drugs have limited their clinical application. In this study, dual-ligand liposomes modified with glycyrrhetinic acid (GA) and cyclic arginine-glycine-aspartic acid (cRGD) (GA/cRGD-LP) were designed to target the GA receptor and αvβ3 integrin, respectively. The aim was to develop a highly selective targeted drug delivery system and further enhance the antitumor efficiency of drugs by targeting both hepatic tumor cells and vasculature. A novel lipid conjugate (mGA-DOPE) by coupling dioleoylphosphatidyl ethanolamine (DOPE) with methyl glycyrrhetinic acid (mGA) was synthesized, and its structure was confirmed. The targeting efficiency of GA/cRGD-LP by in vitro cellular uptake and ex vivo imaging was assessed. GA- and cRGD-modified doxorubicin-loaded liposomes (GA/cRGD-LP-DOX) were prepared, and their cytotoxicity in HepG2 and antitumor activity were evaluated. The results showed that the average particle size of the GA/cRGD-LP-DOX was 114 ± 4.3 nm, and the zeta potential was -32.9 ± 2.0 mV. The transmission electron microscopy images showed that the shapes of our liposomes were spherical. cGA/cRGD-LP-DOX displayed an excellent cellular uptake in both HepG2 and human umbilical vein endothelial cells. In the in vivo study, pharmacokinetic parameters indicated that cGA/cRGD-LP can prolong the circulation time of DOX in the blood. GA/cRGD-LP-DOX showed greater inhibition of tumor growth for HepG2-bearing mice than either the single-ligand-modified liposomes or nontargeted liposomes. GA/cRGD-LP-DOX displayed higher liver tumor localization than that of single-ligand-modified liposomes or free DOX. GA/cRGD-LP is a promising drug delivery system for liver cancer targeting and therapy and is worthy of further study.

100 Deals associated with Grand Pharmaceutical (China) Co., Ltd.

100 Translational Medicine associated with Grand Pharmaceutical (China) Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

IND Application

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

NDA/BLA

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

An'ningpai changrongruan jiaonang	Sinusitis More	Approved
Pyridoxine Hydrochloride	Vitamin B 6 Deficiency More	Approved
Cromolyn Sodium	Asthma More	Approved
Ethambutol Hydrochloride ( rpoB )	Tuberculosis More	Approved
Furosemide ( NKCC2 )	Hypertension More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis